Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating noninfectious pulmonary complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, predictive tools for BOS are not available. We aimed to identify the clinical risk factors and establi...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2024-02, Vol.59 (2), p.239-246
Main Authors: Huang, Qiu-Sha, Han, Tian-Xiao, Chen, Qi, Wu, Jin, Zhao, Peng, Wu, Ye-Jun, He, Yun, Zhu, Xiao-Lu, Fu, Hai-Xia, Wang, Feng-Rong, Zhang, Yuan-Yuan, Mo, Xiao-Dong, Han, Wei, Yan, Chen-Hua, Wang, Jing-Zhi, Chen, Huan, Chen, Yu-Hong, Han, Ting-Ting, Lv, Meng, Chen, Yao, Wang, Yu, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun, Zhang, Xiao-Hui
Format: Article
Language:English
Subjects:
692/499
692/699/1541/1990
Allografts
Bronchiolitis obliterans
Bronchiolitis Obliterans - therapy
Bronchiolitis Obliterans Syndrome
Bronchopneumonia
Cell Biology
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic stem cells
Humans
Internal Medicine
Medicine
Medicine & Public Health
Patients
Prognosis
Public Health
Regression coefficients
Regression models
Retrospective Studies
Risk Factors
Stem cell transplantation
Stem Cells
Transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating noninfectious pulmonary complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, predictive tools for BOS are not available. We aimed to identify the clinical risk factors and establish a prognostic model for BOS in patients who undergo allo-HSCT. We retrospectively identified a cohort comprising 195 BOS patients from 6100 consecutive patients who were allografted between 2008 and 2022. The entire cohort was divided into a derivation cohort and a validation cohort based on the time of transplantation. Via multivariable Cox regression methods, declining forced expiratory volume at 1 s (FEV1) to
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-023-02151-9